Table of Contents
PPT Slide
Safe Harbor Statement
Building a Biopharmaceutical Company
Executing to Plan
Significant Presence at 2004 ADA Meeting
Continued Progress on Exenatide
Improving Delivery – Exenatide LAR
Robust Product Pipeline
2004 Corporate Goals
Exenatide Clinical Leadership
PPT Slide
Type 2 Diabetes Needs New Treatments
Type 2 Diabetes: The Underlying Defects
Beta-cell Defect
Exenatide Targets Beta Cells
Exenatide Restored First Phase Insulin
Exenatide in Clinical Practice
PPT Slide
Exenatide Pivotal Studies
Exenatide Pivotal Studies (AMIGOs)
Consistent Demographics Across AMIGOs
Exenatide Lowered A1C
Exenatide Lowered Fasting Plasma Glucose
Exenatide Improved Postprandial Glucose
Exenatide Lowered Body Weight
Combined AMIGOs: Adverse Events
Combined AMIGOs: Adverse Events
AMIGOs: Summary
Antibody Formation
Exenatide Showed Durable Effect on A1C
Exenatide Showed Durable Effect on Weight
Exenatide: Potential Type 2 Diabetes Therapy
PPT Slide
|